1Tenenbaum A, Fisman EZ. Which is the best lipid - modifying strategy in metabolic syndrome and diabetes: fibrates, smtins or both? Cardiovase Diabetol 2004 ,3 : 10.
2Bloomfield HE. The role of fibrates in a statin world. Arch Intern Med 2006,166:715 -716.
3Verges B. Clinical interest of PPARs ligands. Diabetes Metab 2004 ,30:7 - 12.
4Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high - density lipoprotein cholesterol. Veterans Affairs High - Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999,341:410 -418.
5Rubins HB, Robins S J, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high - density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002,162:2597 -2604.
